Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma

Emily M. Stein, Cristina Rivera

Research output: Contribution to journalArticle

18 Scopus citations


Lenalidomide, a recently developed immunomodulatory drug, shares the antiangiogenic and antitumor properties of thalidomide. While there is a known association between thalidomide and hypothyroidism, to our knowledge, there have been no prior reports of thyrotoxicosis associated with thalidomide or lenalidomide treatment. Herein, we report the case of a patient who developed transient thyrotoxicosis while receiving lenalidomide in a clinical trial for metastatic renal cell carcinoma. The time course and biochemical features of this patient's presentation are most consistent with immune-mediated subacute destructive thyroiditis. This case highlights the importance of monitoring thyroid function in the growing number of patients being treated with lenalidomide.

Original languageEnglish (US)
Pages (from-to)681-683
Number of pages3
Issue number7
Publication statusPublished - Jul 1 2007
Externally publishedYes


ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this